Autosomal Recessive Spastic Ataxia of Charlevoix–Saguenay due to Novel Mutations in the SACS Gene

Abstract

Autosomal recessive spastic ataxia of Charlevoix–Saguenay (ARSACS) is characterized by triad of progressive cerebellar ataxia, progressive spasticity, and axonal/demyelinating peripheral neuropathy. Other manifestations include dysarthria, weakness in lower extremities and distal muscle wasting, foot deformities, retinal striation, prolapse of the mitral valve and rarely intellectual disability, hearing loss, and myoclonic epilepsy. We describe a patient who developed peripheral sensorimotor neuropathy in the absence of spasticity on initial presentation. He had nerve root enhancement on magnetic resonance imaging (MRI) lumbar spine, and nerve conduction studies were suggestive of demyelinating polyneuropathy. Patient had mild cerebellar atrophy on MRI and some delay of motor milestones. Over the course of several months, he developed spasticity, and genetic analysis together with clinical presentation was consistent with ARSACS. He was noted to have a pathogenic mutation c.8108G>A (p. Arg2703His) inherited from mother and a variant of uncertain significance c.7216T>C (p. Ser2406Pro) inherited from his father in SACS gene. Atypical cases may present later in life or in absence of one of the classical features at the time of presentation, which may make diagnosis difficult. Our patient had such an atypical presentation of ARSACS. Young patients with neuropathy and concomitant cerebellar atrophy on MRI should raise suspicion for hereditary spastic ataxia syndrome. Follow-up examination can often reveal additional findings to aid the diagnosis.

Keywords

ARSACS autosomal recessive spastic ataxia of Charlevoix–Saguenay chronic inflammatory demyelinating polyradiculoneuropathy CIDP hereditary polyneuropathy

Case

The patient is a 14-year-old boy who presented with several year history of gait abnormality. He was born at term with no perinatal complications. He had delayed motor milestones. He was not able to pull himself up until the age of 1 year and started walking at the age of 2 years. He was noted to be clumsy and had frequent falls. His speech and language development were reportedly normal. He required physical therapy until middle school. At the age of 7 years, his neurologic examination was reportedly normal, and magnetic resonance imaging (MRI) brain showed mild cerebellar atrophy. His medical history and family history were otherwise non-contributory. Physical examination at the age of 14 years showed high arched palate and pes cavus.

Neurologic examination revealed low tone at ankles, mild atrophy of intrinsic hand and foot muscles, weakness of ankle dorsiflexors (4/5), and toe extensors (3/5) bilaterally. n=No ataxia was noted, Reflexes were absent at ankles, and Romberg’s was positive. Labs including blood counts, metabolic panel, vitamin B12, B1, B2, folate, Gliadin IgG/IgA, and tissue transglutaminase IgA/IgG were normal. The MRI brain revealed mild atrophy of cerebellar hemispheres and vermis. The MRI spine showed diffuse smooth thickening of bilateral brachial plexus, intracostal nerves, and lumbar and sacral plexus with diffuse thickening and enhancement of the cauda equina nerve roots (Figures 1 and 2).

Figure 1.

Magnetic resonance imaging brain findings in our patient. (A) Sagittal T1 image showing cerebellar atrophy. (B) Axial T2 FLAIR (Fluid Attenuted Inversion Recovery) image showing normal cerebral cortex.

Figure 2.

Magnetic resonance imaging lumbar spine with contrast showing nerve root enhancement.

Cerebrospinal fluid (CSF) studies revealed normal glucose (51 mg/dL) and cell count (RBC 1, WBC 1) but elevated protein 106 mg/dL. Electomyography (EMG)/nerve conduction studies revealed markedly prolonged distal latencies with decreased velocities and reduced amplitude in motor nerves in bilateral upper and lower extremities.Sensory responses were unevocable (Table 1). Active and chronic neurogenic changes were noted in right tibialis anterior and gastrocnemius muscles. Patient was started on monthly intravenous immunoglobulin (IVIG) therapy for presumed chronic inflammatory demyelinating polyneuropathy. He underwent extensive evaluation for acquired causes of neuropathy which were unrevealing. He had normal acylcarnitine profile and lactate and pyruvate levels. Patient did not show any improvement in the next 6 months, and IVIG infusions were discontinued. At this time, genetic testing for inherited neuropathies and other neuromuscular conditions was sent. Testing showed a heterozygous variant of uncertain significance, c.80T>C (p. Val27Ala), in FIG4 gene which is associated with autosomal recessive Charcot Marie Tooth disease type 4J. This would not explain his clinical presentation.

Table 1.

Nerve Conduction Study Findings in Our Patient at Initial Presentation and at 1-Year Follow-up.

Nerve	Stimulus	Recording site	Latency (ms)	Amplitude (motor = mV, sensory = µV)	Conduction velocity (m/s)
Initial presentation
Motor nerve conduction studies
Right median	Wrist	APB	7	8.1
Right median	Elbow	APB	13.3	8.1	35
Right ulnar	Wrist	ADM	5.2	8.0
	Below elbow	ADM	10.3	7.9	35
	Above elbow	ADM	12.8	7.9	40
Right tibial	Ankle	AH	26.8	0.3
Right tibial	Popliteal fossa	AH	45.0	0.3	15
Right peroneal	Ankle	EDB	21.0	0.1
	Fibula head	EDB	45.1	0.1	10
	Popliteal fossa	EDB	No response	No response
Sensory nerve conduction studies
Right sural, median, and ulnar sensory responses were unevocable
At 1-year follow-up
Motor nerve conduction studies
Right median	Wrist	APB	7	9.0
Right median	Elbow	APB	12.8	8.6	36
Right ulnar	Wrist	ADM	5.7	9.3
	Below elbow	ADM	10.9	9.3	40
	Above elbow	ADM	13.4	8.9	40
Right tibial	Ankle	AH	27.4	0.3
Right tibial	Popliteal fossa	AH	47.4	0.2	16
Right peroneal	Ankle	EDB	20.2	0.2
	Fibula head	EDB	44.8	0.1	11
	Popliteal fossa	EDB	No response	No response
Right peroneal	Fibula head	TA	2.1	1.1
Right peroneal	Popliteal fossa	TA	No response	No response
Sensory nerve conduction studies
Right radial	Forearm	Forearm-snuff box	7.5	8	13
Right sural, median, and ulnar sensory responses were unevocable

Abbreviations: ms, milliseconds; mV, millivolts; µV, microvolts; m/s, meter/second; APB, abductor pollicis brevis; ADM, abductor digitorum minimi; AH, abductor hallucis; EDB, extensor digitorum minimi; TA, tibialis anterior.

A repeat EMG nerve conduction studies done a year later showed stable findings consistent with a chronic, length-dependent, demyelinating, sensory motor polyneuropathy. There were markedly prolonged distal latencies with reduced amplitude and slowing of the conduction velocity in the demyelinating range of the right tibial and peroneal motor responses. Right medial and ulnar motor responses showed prolonged distal latencies and slowing of the conduction velocity. Right median and ulnar F-wave latencies were prolonged as well. Right sural, median, and ulnar sensory responses were unevocable. Right radial sensory response showed prolonged peak latency, reduced amplitude, and slowing of the conduction velocity in the demyelinating range (Table 1).

Patient was later found to have mild spasticity in his bilateral lower extremities and appendicular ataxia on the follow-up visit. Whole exome sequencing was sent which revealed 2 heterozygous variants in SACS gene: a pathogenic variant c.8108G>A (p.Arg2703His) inherited from mother and a variant of uncertain significance c.7216T>C (p.Ser2406Pro) inherited from his father. The c.8108G>A sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 2703 of the SACS protein. This missense change had not been reported in patients with autosomal recessive spastic ataxia of Charlevoix–Saguenay (ARSACS). This variant is listed in ClinVar with conflicting interpretations, the most recent being pathogenic.^1,2 Advanced modeling of protein sequence and biophysical properties performed at the lab that conducted this testing indicated that this missense variant was expected to disrupt SACS protein function. This variant was determined to be pathogenic. The c.7216T>C variant inherited from his father replaces serine with proline at codon 2406 of the SACS protein. This variant is not present in population databases.

Based on his clinical presentation of ataxia, spasticity, neuropathy, and cerebellar atrophy, and genotypic findings, he was diagnosed with ARSACS. His ophthalmologic examination and echocardiogram were unremarkable. He remained stable at his most recent follow-up at the age of 18 years.

Discussion

Charlevoix–Saguenay spastic ataxia is a autosomal recessive hereditary ataxia syndrome that was first diagnosed in regions of Charlevoix and Saguenay-Lac-St-Jean in Quebec, Canada.³ It is caused by mutations in SACS gene on chromosome 13 which encodes the protein Sacsin.⁴ There are several specific mutations that are linked to familial clusters, and several distinct mutations have been reported for sporadic cases.⁵ Both intra- and interfamilial phenotypic variability has been observed in ARSACS.⁶

The ARSACS is characterized by a triad of progressive cerebellar ataxia, progressive spasticity, and axonal/demyelinating peripheral neuropathy, and may manifest with myriad of features such as dysarthria, weakness in lower extremities and distal muscle wasting, foot deformities, retinal striation, prolapse of the mitral valve and rarely intellectual disability, hearing loss, and myoclonic epilepsy.^1,3,6-9 It typically manifests with gait ataxia in the first decade of life with progressive decline over the next few decades, with patient becoming wheelchair-bound by the fifth decade of life.¹⁰ Some patients can manifest with atypical cases that may present later in life or in absence of one of the classical features at the time of presentation.^11-13 Postmortem studies have revealed cerebellar atrophy with absence of Purkinje cells and spino-cerebellar demyelination.¹⁴ Nerve conduction studies usually reveal neuropathy with demyelinating features¹⁵ but may present with axonal polyneuropathy as well.¹⁰

Our patient initially presented with marked demyelinating neuropathy without any involvement of other organ systems. It was not until the patient developed spasticity and ataxia that was perceived on the follow-up visit that the suspicion for spastic ataxia was raised. His genetic studies revealed one pathogenic mutation and one variant of uncertain significance in SACS gene inherited from his asymptomatic mother and father, respectively. Both parents were completely asymptomatic and were carriers of these changes. It is possible that the confluence of these 2 variants caused a milder version of spastic paraparesis where the neuropathy presented prior to the spasticity. Nerve root enhancement on MRI is often seen with inflammatory neuropathies but can also be seen in patients with hereditary neuropathies¹⁶ as this case, which can confound the clinical picture.

Conclusion

Autosomal recessive spastic ataxia or Charlevoix–Saguenay spastic ataxia can manifest as demyelinating polyneuropathy at first presentation, and index of suspicion should be higher in young patients with cerebellar atrophy in the brain imaging. The novel variants in SACS gene noted in our patient should be added to the repertoire of pathogenic variants causing ARSACS.

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical Approval

Our institution does not require ethical approval for reporting individual cases or case series.

Informed Consent

Verbal informed consent was obtained from a legally authorized representative for anonymized patient information to be published in this article.

ORCID iD

Rohan Sharma

References

Pilliod

Moutton

Lavie

, et al. New practical definitions for the diagnosis of autosomal recessive spastic ataxia of Charlevoix-Saguenay. Ann of Neurol. 2015;78:871-886.

Coutelier

Hammer

Stevanin

, et al. Efficacy of exome-targeted capture sequencing to detect mutations in known cerebellar ataxia genes. JAMA Neurol. 2018;75:591-599.

Bouchard

Barbeau

Bouchard

, et al. Autosomal recessive spastic ataxia of Charlevoix-Saguenay. Can J Neurol Sci. 1978;5:61-69.

Bouhlal

Amouri

El Euch-Fayeche

Hentati

Autosomal recessive spastic ataxia of Charlevoix–Saguenay: an overview. Parkinsonism Relat Disord. 2011;17(6):418-422.

Al-Ajmi

Shamsah

Janicijevic

, et al. Novel frameshift mutation in the SACS gene causing spastic ataxia of Charlevoix-Saguenay in a consanguineous family from the Arabian Peninsula: a case report and review of literature. World J Clin Cases. 2020;8:1477-1488.

Briand

Rodrigue

Lessard

, et al. Expanding the clinical description of autosomal recessive spastic ataxia of Charlevoix-Saguenay. J Neurol Sci. 2019;400:39-41.

Vergano

van der Sluijs

Santen

, et al. ARID1B-Related Disorder. Seattle; 2019.

Ali

Klar

Jameel

, et al. Novel SACS mutations associated with intellectual disability, epilepsy and widespread supratentorial abnormalities. J Neurol Sci. 2016;371:105-111.

Nascimento

Canafoglia

Aljaafari

, et al. Progressive myoclonus epilepsy associated with SACS gene mutations. Neurol Genet. 2016;2(4):e83.

10.

Takiyama

Autosomal recessive spastic ataxia of Charlevoix-Saguenay. Neuropathology. 2006;26:368-375.

11.

Baets

Deconinck

Smets

, et al. Mutations in <em>SACS</em> cause atypical and late-onset forms of ARSACS. Neurology. 2010;75:1181-1188.

12.

Shimazaki

Takiyama

Sakoe

, et al. A phenotype without spasticity in sacsin-related ataxia. Neurology. 2005;64:2129-2131.

13.

Shimazaki

Sakoe

Niijima

, et al. An unusual case of a spasticity-lacking phenotype with a novel SACS mutation. J Neurol Sci. 2007;255:87-89.

14.

Bouchard

JP.

Recessive spastic ataxia of Charlevoix-Saguenay. Handb Clin Neurol. 1991;60:451-459.

15.

Gazulla

Benavente

Vela

, et al. New findings in the ataxia of Charlevoix–Saguenay. J Neurol. 2012;259(5):869-878.

16.

Cellerini

Salti

Desideri

Marconi

MR imaging of the cauda equina in hereditary motor sensory neuropathies: correlations with sural nerve biopsy. AJNR Am J Neuroradiol. 2000;21(10):1793-1798.